Duopharma Biotech Bhd (7148) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Duopharma Biotech Bhd (7148) has a cash flow conversion efficiency ratio of 0.033x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RM25.12 Million ≈ $6.31 Million USD) by net assets (RM757.35 Million ≈ $190.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Duopharma Biotech Bhd worth for the company's overall valuation and market capitalisation.
Duopharma Biotech Bhd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Duopharma Biotech Bhd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 7148 live share price for real-time trading data and today's change.
Duopharma Biotech Bhd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Duopharma Biotech Bhd ranked by their cash flow conversion efficiency. Review 7148 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seneca Foods Corp B
NASDAQ:SENEB
|
0.044x |
|
DB Financial Investment Co Ltd
KO:016610
|
-0.271x |
|
Empresas Tricot S.A
SN:TRICOT
|
0.095x |
|
Roman DBDR Acquisition Corp. II Unit
NASDAQ:DRDBU
|
-0.001x |
|
Strike Energy Ltd
AU:STX
|
0.079x |
|
Hubtown Limited
NSE:HUBTOWN
|
0.035x |
|
Erdene Resource Development Corp
TO:ERD
|
-0.018x |
|
Marine Products Corporation
NYSE:MPX
|
0.077x |
Annual Cash Flow Conversion Efficiency for Duopharma Biotech Bhd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Duopharma Biotech Bhd from 2006 to 2025. Also see Duopharma Biotech Bhd balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | RM757.62 Million ≈ $190.21 Million |
RM112.71 Million ≈ $28.30 Million |
0.149x | +28.40% |
| 2024-12-31 | RM709.15 Million ≈ $178.04 Million |
RM82.16 Million ≈ $20.63 Million |
0.116x | +54.42% |
| 2023-12-31 | RM687.12 Million ≈ $172.51 Million |
RM51.55 Million ≈ $12.94 Million |
0.075x | -30.04% |
| 2022-12-31 | RM655.22 Million ≈ $164.50 Million |
RM70.27 Million ≈ $17.64 Million |
0.107x | +54.89% |
| 2021-12-31 | RM624.00 Million ≈ $156.67 Million |
RM43.20 Million ≈ $10.85 Million |
0.069x | -37.52% |
| 2020-12-31 | RM643.82 Million ≈ $161.64 Million |
RM71.35 Million ≈ $17.91 Million |
0.111x | -12.32% |
| 2019-12-31 | RM529.75 Million ≈ $133.00 Million |
RM66.96 Million ≈ $16.81 Million |
0.126x | -15.94% |
| 2018-12-31 | RM481.04 Million ≈ $120.77 Million |
RM72.33 Million ≈ $18.16 Million |
0.150x | +28.73% |
| 2017-12-31 | RM479.87 Million ≈ $120.48 Million |
RM56.05 Million ≈ $14.07 Million |
0.117x | +59.71% |
| 2016-12-31 | RM454.52 Million ≈ $114.11 Million |
RM33.24 Million ≈ $8.35 Million |
0.073x | +164.65% |
| 2015-12-31 | RM449.72 Million ≈ $112.91 Million |
RM-50.88 Million ≈ $-12.77 Million |
-0.113x | -160.89% |
| 2014-12-31 | RM193.63 Million ≈ $48.61 Million |
RM35.97 Million ≈ $9.03 Million |
0.186x | -14.16% |
| 2013-12-31 | RM182.65 Million ≈ $45.86 Million |
RM39.53 Million ≈ $9.93 Million |
0.216x | -4.12% |
| 2012-12-31 | RM170.50 Million ≈ $42.81 Million |
RM38.49 Million ≈ $9.66 Million |
0.226x | +91.65% |
| 2011-12-31 | RM164.44 Million ≈ $41.29 Million |
RM19.37 Million ≈ $4.86 Million |
0.118x | -53.56% |
| 2010-12-31 | RM157.87 Million ≈ $39.64 Million |
RM40.04 Million ≈ $10.05 Million |
0.254x | +33.09% |
| 2009-12-31 | RM142.74 Million ≈ $35.84 Million |
RM27.20 Million ≈ $6.83 Million |
0.191x | -5.97% |
| 2008-12-31 | RM130.55 Million ≈ $32.78 Million |
RM26.46 Million ≈ $6.64 Million |
0.203x | -7.77% |
| 2007-12-31 | RM114.21 Million ≈ $28.68 Million |
RM25.10 Million ≈ $6.30 Million |
0.220x | +18.17% |
| 2006-12-31 | RM145.43 Million ≈ $36.51 Million |
RM27.04 Million ≈ $6.79 Million |
0.186x | -- |
About Duopharma Biotech Bhd
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives… Read more